Washington, DC—The Alliance to Protect Medical Innovation’s Executive Director Patrick O’Connor released the following statement on the president’s new healthcare executive order:
“Why would the Trump administration adopt a policy to limit Americans’ access to breakthrough treatments at the height of a global pandemic? The administration was smart to abandon this idea the first time around, after countless academics and advocates convinced them it would limit the availability of critical treatments and dramatically reduce spending on research to develop the next wave of innovation. Its revival is a testament to the ego and bankroll of John Arnold and his willingness to spend tens of millions of dollars carrying water for the insurance industry.”
The Alliance to Protect Medical Innovation is a nonpartisan group committed to fostering a national conversation on medical innovation and patient access to care that is holistic and fact-based. The Alliance evaluates policy proposals and fact-checks claims affecting biomedical innovation, as well as responds to attacks on this innovation ecosystem. We are committed to preserving the pipeline of breakthrough medicines that reduce costs within the health care system and help people live longer, healthier, and more productive lives. The Alliance receives funding from biopharmaceutical companies and other entities that represent the industry.
Read our earlier blog posts on the Arnolds’ multimillion investment in influencing the drug-price debate and on the International Price Index.